Malnutrition and cachexia in patients are significant problems due to a variety of mechanisms involving the disease, the host response to the pathologies, and their therapies [1]. Malnutrition has been associated with a number of clinical consequences, including deteriorated quality of life, decreased response to treatment, increased risk of chemotherapy-induced toxicity and a reduction in disease survival [2]. There are various methods of assessing nutritional status in various pathologies, each with its own advantages and disadvantages [3]. Among the most commonly used tools to measure nutritional status are subjective global assessment (SGA) [4,5], bioelectrical impedance analysis (BIA) [6], and laboratory measurements of serum albumin [7], prealbumin, and transferrin [8,9]. Others include anthropometric parameters [10,11,12] such as weight loss, arm muscle circumference, skin-fold thickness [13], and presence of edema and ascites [14]. Though SGA is easy-to-use, inexpensive, and noninvasive, it is subjectively assessed and hence can be affected by inter-observer variation. Similarly, though BIA is easy-to-use, noninvasive, and reproducible, it relies on regression models derived in restricted samples of human subjects, which thus limits the usefulness of the derived model in other patients who differ from the original sample [15].

Serum albumin provides a simple method of estimating visceral protein function. Malnutrition and inflammation suppress albumin synthesis [16]. In an adult the normal range of serum albumin is defined as 3.5-5.0 g/dL and levels <3.5 g/dL is called hypoalbuminemia [2,3]. The inverse correlation between body weight index and albumin synthesis in patients supports the possibility of a compensatory enhanced albumin synthesis in these metabolically affected patients. In the later stages of disease, malnutrition and inflammation suppress albumin synthesis [17]. As part of the systemic inflammatory response to the various pathologies, proinflammatory cytokines and growth factors are released [18] and have a profound catabolic effect on host metabolism. Interleukin-6, produced by the disease, stimulates liver production of acute-phase reaction proteins (such as C-reactive protein (CRP) and fibrinogen) in both the fasted and fed states. This increases the demand for certain amino acids, which if limited in the diet, may be obtained from breakdown of skeletal muscle. The lower serum albumin concentration may be due to the production of cytokines such as IL-6, which modulate the production of albumin by hepatocytes [19].

Serum albumin is generally used to assess the nutritional status, severity of disease, disease progression and prognosis. In the hospital setting, many reports have related serum albumin level to in-hospital mortality, length of stay (LOS), and nosocomial infection. Serum albumin has also been described as an independent prognosticator of survival in various diseases of lung, pancreatic, gastric, colorectal and breast. Low serum albumin has also been described as an independent prognosticator of survival in various diseases of lung, pancreatic, gastric, colorectal and breast. Low serum albumin has also been shown to be an independent indicator for prognosis in patients. However, these studies differ from each other with regard to population studied, study design, sample size, definition of low serum albumin used and factors adjusted for in the analyses.

Keywords: Albumin, prognosis, Hospitalized, Patients.
shown to be an independent indicator for prognosis in patients. However, these studies differ from each other with regard to population studied, study design, sample size, definition of low serum albumin used and factors adjusted for in the analyses.

**Aims and Objectives**
1. To estimate the mean serum albumin levels in hospitalised patients.
2. To correlate the serum albumin levels and the prognosis of the patient.

**Methods**
The present study was conducted in the Department of General Medicine, Azeezia Institute of Medical Sciences and research, Kollam, Kerala.

120 patients were chosen for the study who were confirmed cases of Dengue.

The study was done from July 2017 to March 2019.

The study is a cross-sectional study. The study is also double blinded and randomised. The study is a multi-level study. The sample size included one hundred patients. One hundred and twenty patients were identified in the department of Medicine. The patients were either chronically ill who were hospitalised for more than three weeks.

The serum albumin levels were estimated. In chronically hospitalised patients the patients were divided into three groups:
1. Serum levels less than 2 gm / Dl
2. Serum levels between 2 g/ dl and 5 gm / Dl
3. Serum levels more than 5 gm / Dl

The serum albumin levels were again estimated and the prognosis was checked in the form of non-wound healing, pain, worsening of symptoms, intra surgical complications, post-operative sepsis and death.

In each group the necessary treatment was given in the form of nutrition supplementation and was observed for the prognosis.

The serum albumin levels were again estimated and the prognosis was checked in the form of non-wound healing, pain, worsening of symptoms and death.

**Inclusion criteria**
1. The patients were aged between 20 to 50 years. This was done in order to minimize the age related bias.
2. The patients who were chronically hospitalised were taken for the study.

**Exclusion criteria**
1. Patients who were on drugs which were known to cause low serum albumin.
2. Chronic liver disease.
3. < 20 years and more than > 50 years.

**Results**

**Table 1:** Frequency of patients in each of the divided groups.

| Serum Albumin Level | Number of Patients |
|---------------------|--------------------|
| Group 1 (<2 gm / Dl) | 62                 |
| Group 2 (2 - 5 gm / Dl) | 54               |
| Group 3 (> 5 gm / Dl) | 04                 |

**Table 2:** Mean Serum Albumin Level in each of the divided groups.

| Serum Albumin Level | Mean Serum Albumin Level |
|---------------------|--------------------------|
| Group 1 (<2 gm / Dl) | 1.88 gm / Dl             |
| Group 2 (2 - 5 gm / Dl) | 2.64 gm / Dl         |
| Group 3 (> 5 gm / Dl) | 5.17 gm / Dl             |
functions. Biochemically the albumin coagulates on heating, it is easily soluble in water and it contains a net negative charge. Due to these properties there are many physiological functions that are carried out by this amazing protein. The normal serum level that is found in the normal adult is around three to five grams per deciliter. Anything below two grams per deciliter is considered to be low. In cases of a pathological state there might be a low formation of the albumin in liver or high degradation of the albumin. In either of the ways the serum albumin will be lowered. Stress and strain is also known to cause hypoalbuminemia i.e low serum level of albumin. Since albumin is a protein it has to be transcribed rom the genes and studies have shown that TNF - alpha supresses this transcription process \[^{14, 3, 9}\]. The TNF – alpha is known to increase in any inflammation and thus a forms a cascade. In case of hospitalised patients the stress and strain in pre surgical patients and chronically hospitalised patients the serum albumin levels are known to be less than normal. In chronically hospitalised patients the nutritional cause can also be taken into consideration for lower serum albumin levels. Early detection of these low levels of serum albumin levels helps the surgeons and the physicians to intervene and thus cut off the progression of the disease. \[^{7 - 11}\] A sincere effort has been made in this study to understand the relations of the serum albumin level and its effects on the prognosis of the disease. This study is intended to help the physician, surgeon and general practitioners to understand and intervene in the event and thus help the patient to recover earlier and in a better way.

**Conclusion:**

In the present study there is a significant difference in the prognosis of the patients when the serum albumin level increases in the serum.

**References**

1. Von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005;9(2):S35-S38.
2. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491-497.
3. Sarhili N, Mahmoud FA, Christie R, Tahir A. Assessment of nutritional status and fluid deficits in advanced cancer. Am J Hosp
4. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr 2002;56:779-785.
5. Gupta D, Lammersfeld CA, Vashi PG, Burrows J, Lis CG, Grutsch JF. Prognostic significance of Subjective Global Assessment (SGA) in advanced colorectal cancer. Eur J Clin Nutr 2005;59:35-40.
6. Laky B, Janda M, Cleghorn G, Obermair A. Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. Am J Clin Nutr 2008;87:1678-1685.
7. Gupta D, Lammersfeld CA, Burrows JL, Dahl SL, Vashi PG, Grutsch JF, et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancer. Am J Clin Nutr 2004;80:1634-1638.

**Table 3:** Prognosis table correlation to the serum albumin levels.

| Serum Albumin Level | Prognosis |
|---------------------|-----------|
| Group 1 (<2 gm / Dl ) | Resistant Signs and symptoms: 41 Pain: 10 Worsening of symptoms: 09 Death: 01 |
| Group 2 (2 - 5 gm / Dl ) | Resistant Signs and symptoms: 04 Pain: 1 Worsening of symptoms: NIL Death: NIL |
| Group 3 (> 5 gm / Dl ) | Resistant Signs and symptoms: NIL Pain: NIL Worsening of symptoms: NIL Death: NIL |

**Table 4:** Serum Albumin levels in Post corrected patients after fifteen days of treatment.

| Serum Albumin Level | Mean Serum Albumin Level |
|---------------------|-------------------------|
| Group 1 (<2 gm / Dl ) | 2.94 gm / Dl |
| Group 2 (2 - 5 gm / Dl ) | 5.12 gm / Dl |

**Table 5:** Prognosis in post corrected patients.

| Serum Albumin Level | Prognosis |
|---------------------|-----------|
| Group 1 (<2 gm / Dl ) | Signs and symptoms: NIL Pain: 01 Worsening of symptoms: NIL Death: NIL |
| Group 2 (2 - 5 gm / Dl ) | Signs and symptoms: NIL Pain: NIL Worsening of symptoms: NIL Death: NIL |

**Table 6:** Table of Significance.

| Serum Albumin Level | Significance |
|---------------------|--------------|
| Group 1 (<2 gm / Dl ) | Signs and symptoms: Significant (<0.05 2 tailed) Pain: 05 (<0.05 2 tailed) Worsening of symptoms: 02 (<0.05 2 tailed) Death: NIL (<0.05 2 tailed) |
| Group 2 (2 - 5 gm / Dl ) | Signs and symptoms: NIL (<0.05 2 tailed) Pain: 01 (<0.05 2 tailed) Worsening of symptoms: NIL (<0.05 2 tailed) Death: NIL (Not Significant) |

**Discussion**

The Human liver produces around fifteen grams of albumin per day under normal conditions. The human body is known to degrade about 0.5 to 0.6 grams of total body albumin in a normal adult human being. Around fifty six percent of the total protein in the body is albumin. Before further discussion of the albumin levels in a human body which is under a lot of stress and strain due to pathophysiological processes which has been mentioned in a handful of articles the albumin as a biochemical agent should be checked in brief. Albumin by far is the most abundant protein in the human body and as explained earlier majority of them is produced in the liver. Albumin is a simple protein as it contains only amino – acids and do not contain anything else like metals which influences the function of some proteins. The half - life of the protein albumin is around twenty one days that means around half of the total produced albumin in liver in a single day will be degraded in twenty one days. It has a lot of important physiological
8. McIntosh EN, Laurent LL: Nutritional assessment of the hospitalized patient. Am Fam Physician 1983;27:169-175.

9. Delmore G. Assessment of nutritional status in cancer patients: widely neglected?. Support Care Cancer 1997;5:376-380. 10.1007/s005200050095.

10. Boles JM, Garre MA, Youinou PY. Simple assessment of the nutritional status in the critically ill patient. Resuscitation 1984;11:233-241. 10.1016/0300-9572(84)90020-0.

11. Curtas S, Chapman G, Meguid MM. Evaluation of nutritional status. Nurs Clin North Am 1989;24:301-313.

12. Slaviero KA, Read JA, Clarke SJ, Rivory LP. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy, Nutr Cancer 2003;46:148-157. 10.1207/S15327914NC4602_07.

13. Davies M. Nutritional screening and assessment in cancer-associated malnutrition. Eur J Oncol Nurs 2005;9(2):S64-S73. 10.1016/j.ejon.2005.09.005.

14. Duguet A, Bachmann P, Lallemant Y, Blanc-Vincent MP: Good clinical practice in nutritional management in cancer patients: malnutrition and nutritional assessment. Bull Cancer 1999;86:997-1016.

15. Lukaski HC: Requirements for clinical use of bioelectrical impedance analysis (BIA). Ann N Y Acad Sci 1999;873:72-6. 10.1111/j.1749-6632.1999.tb09451.x.

16. Elia M. The bioimpedance 'craze'. Eur J Clin Nutr 1993:47:825-827.

17. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998;32:S118-S125. 10.1016/S0227-6386(98)70174-X.

18. Ballmer PE, Ochsenbein AF, Schutz-Hofmann S. Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism 1994;43:697-705. 10.1016/0026-0495(94)90117-1.

19. Simons JP, Schols AM, Buurman WA, Wouters EF: Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999;97:215-223. 10.1042/CS19990021.

20. O’Gorman P, McMillan DC, Mc Ardlie CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998;32:76-80.